American Heart Journal
Volume 159, Issue 2 , Pages 222-230.e2 , February 2010

Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)

  • Phillip D. Levy, MD, MPH

      Affiliations

    • Department of Emergency Medicine and the Cardiovascular Research Institute, Wayne State University School of Medicine, Detroit, MI
    • Corresponding Author InformationReprint requests: Phillip D. Levy, MD, MPH, Department of Emergency Medicine, Wayne State University School of Medicine, 4201 St Antoine, Detroit, MI 48201.
    • ,
  • Deepa Nandyal, MD

      Affiliations

    • Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI
    • ,
  • Robert D. Welch, MD, MS

      Affiliations

    • Department of Emergency Medicine and the Cardiovascular Research Institute, Wayne State University School of Medicine, Detroit, MI
    • ,
  • Jie Lena Sun, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Karen Pieper, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Jalal K. Ghali, MD

      Affiliations

    • Department of Cardiology, Detroit Medical Center, Detroit, MI
    • ,
  • Gregg C. Fonarow, MD, FACC

      Affiliations

    • Department of Medicine, Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, Los Angeles, CA
    • ,
  • Mihai Gheorgiade, MD

      Affiliations

    • Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL
    • ,
  • Christopher M. O'Connor, MD

      Affiliations

    • Department of Medicine, Duke University School of Medicine, Durham, NC

Received 29 September 2009 ,Accepted 11 November 2009.

References 

  1. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419–425
  2. Minshall RD, Tan F, Nakamura F, et al. Potentiation of the actions of bradykinin by angiotensin I–converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I–converting enzyme in CHO cells. Circ Res. 1997;81:848–856
  3. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997;79:115–119
  4. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond). 1994;87:567–574
  5. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Circulation. 1998;98:757–765
  6. Peterson JG, Topol EJ, Sapp SK, et al. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med. 2000;109:371–377
  7. Meune C, Mourad JJ, Bergmann JF, et al. Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance. J Renin Angiotensin Aldosterone Syst. 2003;4:149–154
  8. Emanueli C, Maestri R, Corradi D, et al. Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. Circulation. 1999;100:2359–2365
  9. Meune C, Mahe I, Mourad JJ, et al. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Eur J Heart Fail. 2003;5:271–279
  10. Schror K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992;20(Suppl 9):S68–S73
  11. Brunner-La Rocca HP. Interaction of angiotensin-converting enzyme inhibition and aspirin in congestive heart failure: long controversy finally resolved?. Chest. 2003;124:1192–1194
  12. Hall D. Controversies in heart failure. Are beneficial effects of angiotensin-converting enzyme inhibitors attenuated by aspirin in patients with heart failure?. Cardiol Clin. 2001;19:597–603
  13. Konstam MA. Aspirin and heart failure: square evidence meets a round patient. Congest Heart Fail. 2003;9:203–205
  14. Massie BM. Aspirin use in chronic heart failure: what should we recommend to the practitioner?. J Am Coll Cardiol. 2005;46:963–966
  15. Takkouche B, Etminan M, Caamano F, et al. Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis. Drug Saf. 2002;25:373–378
  16. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–776
  17. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587
  18. Willenheimer R, Helmers C, Pantev E, et al. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol. 2002;85:261–270
  19. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821–828
  20. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788
  21. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678–684
  22. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153
  23. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43–51
  24. O'Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2008;156:662–673
  25. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 2002;360:1037–1043
  26. Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157–164
  27. Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119:1616–1624
  28. McAlister FA, Ghali WA, Gong Y, et al. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation. 2006;113:2572–2578
  29. Masoudi FA, Wolfe P, Havranek EP, et al. Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. J Am Coll Cardiol. 2005;46:955–962
  30. Chang S, Kosolcharoen P, Murray D, et al. Lack of interaction between angiotensin receptor blocker and aspirin in patients with heart failure. Circulation. 2006;114:II_767

 The OPTIMIZE-HF registry is registered: www.clinicaltrials.gov, study no. NCT00344513.

 Presented at the American Heart Association Scientific Sessions, New Orleans, LA, November 2009.

PII: S0002-8703(09)00881-3

doi: 10.1016/j.ahj.2009.11.009

American Heart Journal
Volume 159, Issue 2 , Pages 222-230.e2 , February 2010

Article Tools

* Image Usage & Resolution